(Q40778391)

English

No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. (English)

1 reference

Europe PubMed Central

23 September 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

2

object named as

Andreas Stang

1 reference

Europe PubMed Central

23 September 2017

4

object named as

Karel Kostev

1 reference

Europe PubMed Central

23 September 2017

author name string

Bernd Kowall

1

1 reference

Europe PubMed Central

23 September 2017

Wolfgang Rathmann

3

1 reference

Europe PubMed Central

23 September 2017

publication date

1 July 2015

1 reference

Europe PubMed Central

23 September 2017

Pharmacoepidemiology and Drug Safety

1 reference

Europe PubMed Central

23 September 2017

24

1 reference

Europe PubMed Central

23 September 2017

8

1 reference

Europe PubMed Central

23 September 2017

865-874

1 reference

Europe PubMed Central

23 September 2017

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Association of metformin use with cancer incidence and mortality: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Metformin and breast cancer risk: a meta-analysis and critical literature review

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Metformin and the risk of cancer: time-related biases in observational studies

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Metformin and cancer: mounting evidence against an association.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how?

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

The use of metformin and the incidence of lung cancer in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Immortal time bias in pharmaco-epidemiology

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Validation of methods to control for immortal time bias in a pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Comparative lesion sequencing provides insights into tumor evolution

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Medical Record Databases

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3823

21 January 2018

Identifiers

10.1002/PDS.3823

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40778391&oldid=1507195238"